Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioventixBVNXF 57 EV-to-EBIT is 8.92 as of Aug. 23, 2026, which is 58% below its 10-year median of 21.35. GuruFocus rates BVNXF with a GF Score™ of 57/100 and a GF Value™ of $30.35. The stock has 3 warning signs investors should review. Among 376 Biotechnology companies, Bioventix ranks better than 63.03% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bioventix's Enterprise Value for the quarter that ended in Dec. 2025 was $0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bioventix's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $13.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioventix EV-to-EBIT Related Terms
Bioventix EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bioventix's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bioventix's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioventix EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bioventix's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bioventix's EV-to-EBIT falls into.
Bioventix's current Enterprise Value is $117.51 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bioventix's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $13.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioventix (BVNXF) has a EV-to-EBIT of 8.92 as of Aug. 23, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bioventix and its competitors. This is 58% below median its historical median of 21.35. Over the past decade, Bioventix's EV-to-EBIT has ranged from 6.72 to 31.27. According to the industry distribution chart, Bioventix ranks #139 out of 376 companies in the Biotechnology industry, placing it in the top 37%.
Is Bioventix's EV-to-EBIT too high?
Bioventix's current EV-to-EBIT of 8.92 is 58% below median its 10-year median of 21.35. Over the past 10 years, this metric has ranged from a low of 6.72 to a high of 31.27. The Biotechnology industry median EV-to-EBIT is 16.16. Bioventix's value of 8.92 is 44.8% below this industry median. Based on the distribution chart, Bioventix ranks #139 out of 376 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bioventix has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Bioventix's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bioventix ranks #139 out of 376 companies for EV-to-EBIT. This puts Bioventix in the upper half of its industry. The industry median EV-to-EBIT is 16.16. Bioventix's value of 8.92 is 44.8% below this benchmark. Historically, Bioventix's own EV-to-EBIT has ranged from 6.72 to 31.27 over the past decade. While the company's 10-year median is 21.35 vs. the industry median of 16.16, Bioventix has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.16, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioventix's current EV-to-EBIT of 8.92 is 44.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bioventix and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioventix's current EV-to-EBIT is 8.92, which is 58% below median its own 10-year median of 21.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioventix stock overvalued right now?
Bioventix (BVNXF) has a current EV-to-EBIT of 8.92. The stock's GF Value™ is $30.35, compared to a current price of $14.71 — trading 51.5% below its estimated fair value. The current EV-to-EBIT is 8.92, which is 58% below median its 10-year median of 21.35 and 44.8% below the Biotechnology industry median of 16.16. Bioventix's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bioventix (BVNXF), the current EV-to-EBIT is 8.92 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioventix (BVNXF) Overvalued in 2026?
Based on GuruFocus' analysis, Bioventix stock appears to be undervalued.
The current stock price of $14.71 is trading 51.5% below its estimated GF Value™ of $30.35.
Key valuation signals for BVNXF:
EV-to-EBIT: 8.92 (58% below median its 10-year median of 21.35)
GF Value™: $30.35 vs. price of $14.71 (51.5% below fair value)
Industry Position: 44.8% below the Biotechnology median (#139 of 376)
No single metric tells the full story. See the BVNXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
57GF Score
Get the complete analysis for BVNXF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BVNXF has been successfully added to your 
